Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

RECURrence of Atrial Fibrillation After Cardioversion of Patients Randomized to Open-label Treatment With Dapagliflozin or Usual Care

NCT07187570 is registered in ClinicalTrials.gov with Region Stockholm as lead sponsor.

NCT NCT07187570
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07187570 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
RECURrence of Atrial Fibrillation After Cardioversion of Patients Randomized to Open-label Treatment With Dapagliflozin or Usual Care
Lead sponsor
Region Stockholm
Phase
Phase 3
Overall status
Recruiting
Start date
June 3, 2025
Completion date
December 31, 2027
Enrollment
1,600 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

atrial fibrillation (af)